---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019087"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:35:55.182947+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience Q1 cash $3.6M, secures $22M royalty financing; Ovaprene Phase 3 ongoing

## Summary
- Cash & equivalents $3.6M at March 31, 2024; subsequent $22M non-dilutive royalty financing from XOMA and $1M grant installment.
- R&D expenses $3.3M in Q1 2024, down 34% YoY from $5.0M; G&A $2.7M vs $3.3M.
- Ovaprene Phase 3 contraceptive study recruiting at 18 US sites; central ad campaign launched March 2024.
- Sildenafil Cream end-of-Phase 2 meeting with FDA completed; additional feedback expected 2Q2024 for Phase 3 design.
- XACIATO commercialized by Organon since Q4 2023; first FDA-approved product from Daré portfolio.

## SEC filing metadata
- accession: 0001493152-24-019087
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/0001493152-24-019087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019087
- JSON: https://secwatch.observer/filing/0001493152-24-019087.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019087.txt

## Key facts
- Earnings Releases
  Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024, a copy of which is furnished as Exhibit 99.1 to this report.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/0001493152-24-019087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.